Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the effects of PME to those of PSIL on the head twitch response (HTR), neuroplasticity-related synaptic proteins and frontal cortex metabolomic profiles in male C57Bl/6j mice. HTR measurement showed similar effects of PSIL and PME over 20 min. Brain specimens (frontal cortex, hippocampus, amygdala, striatum) were assayed for the synaptic proteins, GAP43, PSD95, synaptophysin and SV2A, using western blots. These proteins may serve as indicators of synaptic plasticity. Three days after treatment, there was minimal increase in synaptic proteins. After 11 days, PSIL and PME significantly increased GAP43 in the frontal cortex ( p = 0.019; p = 0.039 respectively) and hippocampus ( p = 0.015; p = 0.027) and synaptophysin in the hippocampus ( p = 0.041; p = 0.05) and amygdala ( p = 0.035; p = 0.004). PSIL increased SV2A in the amygdala ( p = 0.036) and PME did so in the hippocampus ( p = 0.014). In the striatum, synaptophysin was increased by PME only ( p = 0.023). There were no significant effects of PSIL or PME on PSD95 in any brain area when these were analyzed separately. Nested analysis of variance (ANOVA) showed a significant increase in each of the 4 proteins over all brain areas for PME versus vehicle control, while significant PSIL effects were observed only in the hippocampus and amygdala and were limited to PSD95 and SV2A. Metabolomic analyses of the pre-frontal cortex were performed by untargeted polar metabolomics utilizing capillary electrophoresis – Fourier transform mass spectrometry (CE-FTMS) and showed a differential metabolic separation between PME and vehicle groups. The purines guanosine, hypoxanthine and inosine, associated with oxidative stress and energy production pathways, showed a progressive decline from VEH to PSIL to PME. In conclusion, our synaptic protein findings suggest that PME has a more potent and prolonged effect on synaptic plasticity than PSIL. Our metabolomics data support a gradient of effects from inert vehicle via chemical psilocybin to PME further supporting differential effects. Further studies are needed to confirm and extend these findings and to identify the molecules that may be responsible for the enhanced effects of PME as compared to psilocybin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Proceedings of the National Academy of Sciences
Richards, J. W. (1915) · Science · doi:10.1126/science.42.1074.161 · Cited by 13,983
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
Ruiz-Perez, D., Guan, H., Madhivanan, P., Mathee, K., & Narasimhan, G. (2020) · BMC Bioinformatics · doi:10.1186/s12859-019-3310-7 · Cited by 426
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Cited by
Weiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“A WB study in mice showed an increased expression of molecular biomarkers of synaptic plasticity (SV2A, GAP43, synaptophysin) 11 days after the administration of both synthetic psilocybin and mushroom extract in various brain areas including the prefrontal cortex, hippocampus and amygdala [65].”
Li, G., Wu, Q., Wang, C., Deng, P., Li, J., Zhai, Z., & Li, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-82571-9 · Cited by 40
Brownstien, M., Lazar, M., Botvinnik, A., Shevakh, C., Blakolmer, K., Lerer, L., Lifschytz, T., & Lerer, B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-024-02786-0 · Cited by 30
Self-citationPsilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
“Psychedelic mushroom extract significantly increased GAP43, PSD95, synaptophysin, and SV2A across all brain areas, while psilocybin effects were limited to PSD95 and SV2A in the hippocampus and amygdala (Shahar et al., 2024).”
BackgroundWerle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 26
Hutchison, K. E., Hooper, J. F., & Karoly, H. C. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3038 · Cited by 25
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025) · Journal of Fungi · doi:10.3390/jof11020099 · Cited by 15
“Further research is needed to confirm these observations and identify the specific molecules responsible for the enhanced effects of natural extracts [35].”
Lerer, E., Botvinnik, A., Shahar, O., Grad, M., Blakolmer, K., Shomron, N., Lotan, A., Lerer, B., & Lifschytz, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1391412 · Cited by 17
Self-citationCohen, J., Sulimani, L., Procaccia, S., Lerenthal, Y., Milay, L., Taran, I., Shapira, A., & Meiri, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-97710-z · Cited by 8
“Existing methods integrate a wide range of experimental conditions 44–50 .”
Ortega, A., Martínez-Nuncio, L. A., Taddei, E., Castañeda-Saucedo, E., Rubio, C., & Rubio‐Osornio, M. (2025) · Life · doi:10.3390/life15101505 · Cited by 16
Blest‐Hopley, G., Pasculli, G., Ruffell, S., Tsang, W., Olateju, E., Pate, K. M., Kettner, H., Roseman, L., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1594307 · Cited by 8
Maltby, C. J., Klein, A. K., Paschen, E., Pinto, J., Dvořák, D., Hedde, J. R., Hanks, A. N., Bianchi, M., & Hughes, Z. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251395386 · Cited by 11
“…increase dendritic spine density in the prefrontal cortex (PFC) in vivo (Shao et al., 2021) as well as increase the expression of synaptic plasticity biomarkers, such as brain-derived neurotrophic factor (BDNF) and synaptic vesicle glycoprotein 2A (SV2A) (Raval et al., 2021; Shahar et al., 2024).”
Lazar, M., Brownstien, M., Botvinnik, A., Shevakh, C., Shahar, O., Lifschytz, T., & Lerer, B. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf022 · Cited by 6
“The dose of PSIL that we used (4.4 mg/kg) was chosen based on our previous dose-response study on the effect of PSIL on the head-twitch response 17,18 and in view of the fact this dose is equivalent in mice to a 25 mg dose in humans according to the widely used DoseCal dose conversion methodology.”
InfluentialSelf-citationVaria, J. C., Herbert, M. R., & Hooker, B. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05589-8 · Cited by 9
“…only primary and secondary therapeutic agents (e.g., alkaloids, pre-and postbiotics, antioxidants, and microbial communities living in fermented foods) shown to have therapeutic potential, but also myriad secondary metabolites in the “ nutritional dark matter” in the “ foodome ” [448, 479, 590].”
Díaz-Valdivia, N., Labarca, M., Retamal, C., Espinoza, S., Venegas, J., Catenaccio, A., de la Peña, A., Ricca, M., Jara, C., Cortés-Díaz, D., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01339-7 · Cited by 4
“PSD-95, a core scaffolding protein of the PSD that interacts with NMDARs and AMPARs, stabilizing them at the synapse (Shahar et al. 2024), also remains unchanged in the NSPA-KO mice (Espinoza et al. 2020).”
Syed, O. A., Petranker, R., Fewster, E. C., Sobolenko, V., Beidas, Z., Husain, M. I., Lake, S., & Lucas, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2446445 · Cited by 10
“Another recent study found Psilocybe cubensis extracts to elicit greater and prolonged effects on synaptic plasticity in the mouse brain compared to pure psilocybin (Shahar 2024).”
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia
Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 7
“However, given the evidence that comes from in vitro and animal studies [57,60] and preclinical molecular findings on increased expression of SV2A and several other synaptic proteins in mouse brains [62], it is likely that such modifications would also occur in living human brains.”
Murray, Z., Lewies, A., Wentzel, J. F., Schutte‐Smith, M., Erasmus, E., Noreljaleel, A. E. M., Visser, H. G., Wilhelm, A., & Issahaku, A. R. (2026) · Scientific Reports · doi:10.1038/s41598-026-39483-7 · Cited by 7
“Similarly, Shahar et al. recently investigated the chemical profiles of pure psilocybin and psychedelic mushroom extracts, observing differential effects on synaptic protein levels, potentially indicative of unique neuroplastic responses elicited by the whole extract 13 .”
Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome
Zschoche, N., Schober, S., Walther, K., Chadeayne, A. R., Gressler, M., Bartram, S., O'Connor, S. E., & Hoffmeister, D. (2025) · ChemBioChem · doi:10.1002/cbic.202500167 · Cited by 3
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs
Acero, V. P., Flatt, T. A., Gooch, P. M., Gaughan, S. J., Levin, A. W., & Davis, A. K. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2515866 · Cited by 4
Rached, G., Campana, A. M., Fiani, D., Nguyen, C. Y., den Eynde, V. V., Gillman, P. K., & Barnett, B. S. (2026) · CNS Drugs · doi:10.1007/s40263-025-01256-7 · Cited by 3
Brennan, C. S., Huang, Y., & Brennan, M. A. (2025) · Translational Food Sciences · doi:10.1093/trfood/vxaf001 · Cited by 3
Nogueira, M., García-Hernández, S., Roberto, G. S., & Marques, L. Z. (2024) · International journal of medicinal mushrooms · doi:10.1615/intjmedmushrooms.2024057053 · Cited by 2
Islam, S., Liden, T., Goff, R., & Schug, K. A. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466009 · Cited by 2
Bradshaw, A. J., Sharp, C., van der Merwe, B., Tremble, K., & Dentinger, B. T. M. (2026) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2025.2270 · Cited by 2
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03005-0 · Cited by 2
Sharchaton, A., Parsha, S., Azerrad, S. P., Dekel, Y., Rabah, N., Páleníček, T., & Kurzbaum, E. (2026) · Journal of Fungi · doi:10.3390/jof12070486 · Cited by 1
“…suggests that natu-ral mushroom extracts may produce stronger or more prolonged effects than equivalent doses of synthetic psilocybin, possibly because accompanying indole alkaloids and other compounds, e.g., the betacarbolines, modulate or amplify the action of the primary compound [18,19].”
Nogueira, M., García-Hernández, S., Roberto, G. S., & Marques, L. Z. (2024) · medRxiv · doi:10.1101/2024.07.11.24310147 · Cited by 1
Yun, Y., Lee, S., Mun, S., Kang, H., & Lee, J. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01810-2
“Hypoxanthine is also known to be a metabolite involved in oxidative stress responses and the maintenance of cellular energy homeostasis (Shahar et al. 2024 ) In healthy adults, serum hypoxanthine concentra - tions have been reported to range from approximately 14 to 38 µM (Caussé et al. 2007 ),.…”
Zhang, Y., Pang, Y., Tan, H., Xian, R., Liang, J., Wen, Q., Li, Z., Yan, L., Xie, Z., Liang, J., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1772788 · Cited by 1
“PSD95 and synaptophysin protein levels were used as indicators of synaptic plasticity in hippocampus (Shahar et al., 2024).”
Psilocybin mushrooms are going mainstream, but scientific research and regulation lag behind
Karoly, H. C., & Hutchison, K. E. (2026) · The Conversation · doi:10.64628/aai.6g7fw5d5c
Schober, S., Dorfmann, L., Walther, K., Blei, F., Chadeayne, A. R., Gressler, M., Bartram, S., O'Connor, S. E., & Hoffmeister, D. (2026) · ChemBioChem · doi:10.1002/cbic.70318
Oña, G., Llagostera, C., Alvarez, O., Dueñas, R. M., González, D., & Soto-Angona, Ó. (2026) · Natural Product Research · doi:10.1080/14786419.2026.2683121
Leeman, L., Armstrong, M., Menashi, D., Nayo-Washington, H., Marseille, E. A., Herrera, J., Romero, C., & Page‐Reeves, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1845943
“…psilocybin offers the ability to have a standardized product with regard to strength and composition from a drug-delivery perspective, the use of a whole psilocybe cubensis product could be further beneficial due the potential “entourage” effect of the combination of active compounds (38).”
Enriquez‐Geppert, S., Bevers, L., Rosander, A., Fodran, P., & Polito, V. (2026) · Biomolecules · doi:10.3390/biom16070983
“In contrast, Shahar et al. [145] found similar HRT responses between natural and synthetic compounds.”
Retreat from racism: A psychedelic group experience for racial stress and trauma
Rosal, S. P., Faber, S., MacIntyre, M. M., & Williams, M. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100031
Shahar, O., Botvinnik, A., Chaykin, M., Shwartz, A., Lerer, E., Golding, P., Ari, M. B., Shalev, O., Lifschytz, T., & Lerer, B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743248
“In our recent work comparing chemically synthesized psilocybin (PSIL) with a psychedelic mushroom extract (PME), we observed that PME produced more potent and prolonged increases in synaptic plasticity markers together with distinct frontal-cortex metabolomic signatures 36 .”
Self-citationTai, M. L., Szigeti, B., Downey, A. E., Aday, J. S., Fredenburg, L., Sakai, K., Molina, C., Fernandes‐Osterhold, G., Bradley, E., Pantoni, M. M., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478603
Madhuvilakku, R., Kar, A. K., Roy, T., Shamali, U. K. A., Akter, S., & Hong, Y. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01598k
Metadata
- Authors
- Shahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., Wolf, G., Lotan, A., Lerer, L., Lerer, B., & Lifschytz, T.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Israel Institute for Biological Research (IL)
- Corresponding author
- Lerer, Bernard
- Lifschytz, Tzuri
- Venue
- Molecular Psychiatry
- Published
- 2024-02-20
- Volume
- 29
- Issue
- 7
- Pages
- 2059-2073
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11408259
- OpenAlex
- W4391970820
- Cited by
- 40
- References
- 80
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 8
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Back of the Yards algae sciences (BYAS) and Parow Entheobiosiences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- psilocybin, tryptamine alkaloids, head-twitch response, synaptic plasticity, synaptic proteins, GAP-43, PSD-95, synaptophysin, SV2A, purine metabolism, purine nucleotides, neuroplasticity, mouse brain, hippocampus, amygdala
- MeSH terms
- Agaricales, Animals, Brain, Frontal Lobe, Hallucinogens, Male, Mice, Inbred C57BL, Neuronal Plasticity, Psilocybin, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.